These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 25655798)

  • 1. Recruitment of Donor T Cells to the Eyes During Ocular GVHD in Recipients of MHC-Matched Allogeneic Hematopoietic Stem Cell Transplants.
    Herretes S; Ross DB; Duffort S; Barreras H; Yaohong T; Saeed AM; Murillo JC; Komanduri KV; Levy RB; Perez VL
    Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2348-57. PubMed ID: 25655798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Onset of ocular graft-versus-host disease symptoms after allogeneic hematopoietic stem cell transplantation.
    Shikari H; Amparo F; Saboo U; Dana R
    Cornea; 2015 Mar; 34(3):243-7. PubMed ID: 25603230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.
    Hossain MS; Kunter GM; El-Najjar VF; Jaye DL; Al-Kadhimi Z; Taofeek OK; Li JM; Waller EK
    PLoS One; 2017; 12(9):e0184254. PubMed ID: 28953925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
    Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
    Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programming of donor T cells using allogeneic δ-like ligand 4-positive dendritic cells to reduce GVHD in mice.
    Mochizuki K; Meng L; Mochizuki I; Tong Q; He S; Liu Y; Purushe J; Fung H; Zaidi MR; Zhang Y; Reshef R; Blazar BR; Yagita H; Mineishi S; Zhang Y
    Blood; 2016 Jun; 127(25):3270-80. PubMed ID: 27143255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Scoring Criteria for the Evaluation of Ocular Graft-versus-Host Disease in a Preclinical Allogeneic Hematopoietic Stem Cell Transplantation Animal Model.
    Perez VL; Barsam A; Duffort S; Urbieta M; Barreras H; Lightbourn C; Komanduri KV; Levy RB
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1765-1772. PubMed ID: 27492793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
    Tian Y; Deng YB; Huang YJ; Wang Y
    Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
    Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
    Front Immunol; 2018; 9():3104. PubMed ID: 30733722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Endothelial Activation in a Mouse Model of Graft vs Host Disease Following Chemotherapy.
    Pereira M; Lee NT; Noonan J; Willcox AEH; Calvello I; Georgy SR; Selan C; Chia JS; Hauw W; Wang X; Peter K; Robson SC; Nandurkar HH; Sashindranath M
    Front Immunol; 2021; 12():708554. PubMed ID: 34421913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of graft-versus-host disease in SCID mice and prevention by physicochemical stressors.
    Sheng-Tanner X; McKerlie C; Spaner D
    Transplantation; 2000 Dec; 70(12):1683-93. PubMed ID: 11152097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An essential role for IFN-gamma in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation.
    Asavaroengchai W; Wang H; Wang S; Wang L; Bronson R; Sykes M; Yang YG
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):46-55. PubMed ID: 17222752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conjunctival polyploid cells and donor-derived myofibroblasts in ocular GvHD.
    Hallberg D; Stenberg K; Hanson C; Stenevi U; Brune M
    Bone Marrow Transplant; 2016 May; 51(5):692-7. PubMed ID: 26808567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease.
    Kawasaki Y; Sato K; Hayakawa H; Takayama N; Nakano H; Ito R; Mashima K; Oh I; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Fujiwara SI; Ohmine K; Muroi K; Kanda Y
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1563-1574. PubMed ID: 29678638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
    Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
    Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
    Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling Chronic Graft-versus-Host Disease in MHC-Matched Mouse Strains: Genetics, Graft Composition, and Tissue Targets.
    Müller AMS; Min D; Wernig G; Levy RB; Perez VL; Herretes S; Florek M; Burnett C; Weinberg K; Shizuru JA
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2338-2349. PubMed ID: 31415899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.